DEVELOPMENT OF SPR206, A DIRECT ACTING POLYMYXIN ANTIBIOTIC WITH REDUCED NEPHROTOXICITY, TO TREAT MULTIDRUG-RESISTANT GRAM-NEGATIVE BACTERIAL PATHOGENS

Spero Therapeutics, Inc., Cambridge MA

Investigators